Treatment of dyslexia using botulinum toxin
A method for treating dyslexia or reading developmental disorder (RDD) in a patient in need thereof comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The subcutaneous or intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and/or a sacral nerve of the patient. In infants or toddlers—from about birth to 5 years old, botulinum toxin is used to prevent or minimize damage to the developing brain that would result in dyslexia; in older children and adult patients with dyslexia, botulinum toxin will be used to reduce or eliminate their symptoms.
1. A method for treating dyslexia or reading developmental disorder (RDD) in a patient in need thereof, comprising administering botulinum toxin to the patient, thereby treating dyslexia or RDD, wherein administering for an adult comprises, by subcutaneous or intradermal injection, 1-4 units to and/or around the vicinity of a trigeminal nerve, 1-4 units to and/or around the vicinity of a cervical nerve, lateral to the patient's spine, 1-4 units to and/or around the vicinity of a thoracic nerve, lateral to the patient's spine, 1-4 units to and/or around the vicinity of a lumbar nerve, lateral to the patient's spine, and/or 1-4 units to and/or around the vicinity of a sacral nerve, lateral to the patient's spine, and monitoring if the patient's neuroexcitatory substances levels normalize.
2. The method of claim 1 , wherein the trigeminal nerve comprises an ophthalmic nerve, maxillary nerve, mandibular nerve, supraorbital nerve, supratrochlear nerve, infraorbital nerve, lacrimal nerve, nasociliary nerve, superior alveolar nerve, buccal nerve, lingual nerve, inferior alveolar nerve, mental nerve, an auriculotemporal nerve, lesser occipital nerve, a greater occipital nerve, or a combination thereof.
3. The method of claim 1 , wherein the cervical nerve comprises a c-2 nerve, c-3 nerve, c-4 nerve, c-5 nerve, c-6 nerve, c-7 nerve, c-8 nerve, or a combination thereof.
4. The method of claim 1 , wherein the thoracic nerve comprises a t-2 nerve, t-3 nerve, t-5 nerve, t-6 nerve, t-7 nerve, t-8 nerve, t-9 nerve, t-10 nerve, t-11 nerve, t-12 nerve, or a combination thereof.
5. The method of claim 1 , wherein the lumbar nerve comprises an 1-1 nerve, 1-2 nerve, 1-3 nerve, 1-4 nerve, 1-5 nerve, or a combination thereof.
6. The method of claim 1 , wherein the sacral nerve comprises an s-1 nerve, s-2 nerve, s-3 nerve, s-4 nerve, s-5 nerve, or a combination thereof.
7. The method of claim 1 , wherein the botulinum toxin comprises botulinum toxin type A, botulinum toxin type B, botulinum toxin type C, botulinum toxin type D, botulinum toxin type E, botulinum toxin type F, botulinum toxin type G, a fragment thereof, a hybrid thereof, a chimera thereof, or a combination thereof.
8. The method of claim 1 , wherein each of the subcutaneous or intradermal injection is bilateral.
9. The method of claim 1 , wherein a total dosage of the botulinum toxin for an adult who weighs about 150 lbs is between about 1 unit and about 150 units.
10. The method of claim 9 , wherein a total dosage of the botulinum toxin for an adult, a child over about 5 years old, and a toddler from about 1 to 5 years old is adjusted for age, weight, or a combination thereof.
11. The method of claim 1 , wherein said administering reduces the incidence of dyslexia or RDD in the patient that comprises a toddler from about birth to 5 years old.
12. The method of claim 1 , wherein said administering reduces or eliminates a symptom of the patient with dyslexia or RDD that comprises a child over about 5 years old or an adult.
13. The method of claim 1 , wherein the neuroexcitatory substances are substance P, calcitonin gene-related peptide (CGRP) or glutamate.
14. The method of claim 1 , wherein the monitoring if the patient's neuroexcitatory substances levels normalize comprises monitoring if the patient's blood glutamate level normalizes.
15. The method of claim 1 , wherein if the patient's neuroexcitatory substances levels fail to normalize, additional botulinum toxin is administered to the patient.
16. The method of claim 1 , wherein if the patient's neuroexcitatory substances levels fail to normalize, an antagonist to the neuroexcitatory substances is administered to the patient.
17. The method of claim 1 , wherein the monitoring if the patient's neuroexcitatory substances levels normalize occurs one or two weeks after the administering botulinum toxin to the patient.
18. The method of claim 1 , further comprising monitoring the patient's physical symptoms.
19. The method of claim 18 , wherein if the patient's physical symptom continues, additional botulinum toxin is administered to the patient.
20. The method of claim 18 , wherein if the patient's physical symptom continues, an antagonist to the neuroexcitatory substances is administered to the patient.